<DOC>
	<DOCNO>NCT02753855</DOCNO>
	<brief_summary>The purpose study characterize plasma urinary concentration telavancin follow intravenous administration single dose telavancin healthy subject normal weight , overweight , obese .</brief_summary>
	<brief_title>Pharmacokinetics Telavancin Normal Obese Subjects</brief_title>
	<detailed_description>This study Phase I , open-label , single-dose pharmacokinetic study healthy adult male female subject . Eligible subject assign one four group base body mass index total body weight . Subjects receive single dose telavancin depend subject 's group 1-hour intravenous infusion . Serial blood urine sample collect 12 hour determine serum urinary pharmacokinetics telavancin . Subjects return blood urine sample collection 24 48 hour . Safety evaluation assess throughout study include physical examination , vital sign monitoring , clinical laboratory test , monitor adverse event , marker kidney injury .</detailed_description>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Healthy adult subject , 18 50 year Nonsmokers within last 1 year Weight &gt; 110 lbs History significant hypersensitivity reaction intolerance telavancin Aspartate alanine aminotransferase &gt; 1.5 time upper limit normal Estimated creatinine clearance &lt; 60 mL/minute serum creatinine &gt; 1.5 mg/dL Female subject pregnant breast feed History alcohol substance abuse dependence within last 1 year Use prescription nonprescription drug ( unless hormonal contraceptive ) within 7 14 day prior telavancin administration Participation clinical trial within last 30 day Donated blood ( &gt; 500 mL ) within last 56 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>